Homepage

African trial of novel HIV vaccine candidate starts

Professor Tomas Hanke, Professor of Vaccine Immunology at the Jenner Institute, and lead researcher on the trial, said: ‘This highly rational, bioinformatics-assisted, vaccine design addresses the enormous variability of HIV-1 - one of the greatest challenges to the development of an effective vaccine against HIV/AIDS.’

Applications now open for Vaccinology in Africa Course 2021

The course provides teaching in human and veterinary vaccinology by an exceptional faculty of academic and industrial speakers, with an emphasis on strengthening vaccine development and manufacturing autonomy in Africa. The course alternates between East and West Africa. In 2021, participation is for attendees working or studying in East Africa. Applications close 31 August.

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

T-cell ‘training grounds’ behind robust immune system response seen in adenovirus vaccines

Adenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, may generate robust long-term immune system responses, according to scientists from the Universities of Oxford and the Cantonal Hospital St.Gallen, Switzerland.

HIV vaccine trial starts at Oxford

Vaccinations started today of a novel HIV vaccine candidate as part of a Phase I clinical trial in the UK. Professor Tomáš Hanke, Professor of Vaccine Immunology at the Jenner Institute and lead researcher on the trial, said: ‘An effective HIV vaccine has been elusive for 40 years. This trial is the first in a series of evaluations of this novel vaccine strategy in both HIV-negative individuals for prevention and in people living with HIV for cure.’

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study. Mixed schedules involving Pfizer-BioNTech and Oxford-AstraZeneca generate strong immune response against SARS-CoV2 spike IgG protein.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose. Additionally, a third dose of the vaccine continues to boost antibodies against SARS-CoV-2.

Significant reductions in COVID-19 infections found after single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine

COVID-19 infections fell significantly – by 65% percent - after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study.

African malaria researcher working in the laboratory

Malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal

Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up.

UPDATE ON COVID-19 VACCINE Trial

For all information and enquiries regarding the COVID-19 vaccine trial, please visit: https://covid19vaccinetrial.web.ox.ac.uk/.

SUPPORT OXFORD’S COVID-19 VACCINE RESEARCH

Funding for Oxford’s COVID-19 vaccine research requires unprecedented speed, scope and ambition. Support from Government, corporations, trusts and foundations will be crucial to the development of a vaccine to combat the new virus. Alongside those traditional sources of funding, philanthropic donations of any size will have real and rapid impact, allowing us to accelerate this time-critical research, and ensure that Oxford’s vaccine solution will be as effective and swift as possible.

If you are interested in supporting this effort, please make a gift here.

Seminars

Broadly neutralizing antibodies against HIV and novel vaccine approaches to induce them

Monday, 25 October 2021, 2pm to 3pm
Vaccine Adjuvants for Global Health

Tuesday, 23 November 2021, 1pm to 2pm
The Human Immunomics Initiative: Decoding the human immune system to accelerate development of vaccines and immunotherapies for major infectious diseases and cancers

Monday, 06 December 2021, 3pm to 4pm

Latest publications

Therapeutic vaccination for treatment of chronic hepatitis B.
Journal article

Cargill T. and Barnes E., (2021), Clinical and experimental immunology, 205, 106 - 118
A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa
Journal article

Ndwiga L. et al, (2021), International Journal for Parasitology: Drugs and Drug Resistance, 16, 155 - 161

COVID OUTBREAK

During the COVID-19 pandemic, the Jenner Institute is taking measures to prevent the spread of the disease. Departments are instructed by the University’s Registrar to continue to work from home where possible, and manage the return to on site working, based on the University guidelines for risk assessments and work prioritisation. This is to restrict contact between individuals as far as possible. The University remains open and operating as far as possible with the following restrictions:

- No public access to the University.

- On-site activity permitted where it cannot be undertaken remotely, driven by safety, capacity and other factors such as schools reopening/other changes in government guidelines.

- Teaching and assessment are undertaken remotely where possible and, depending on government guidelines, gatherings of staff and students only permitted where essential for teaching and assessment to take place.

Public Engagement

Tweets by The Jenner Institute

COVID-19 Response

- Protect our community

- Protect the vulnerable

- Protect yourself

To find out more about the University's COVID-19 response and measures of protection: